Hebei Kaiwei Hengcheng Pharmaceutical Co., Ltd., situated in the Zhangjiakou region of Hebei Province, has its origins in the Zhangjiakou Pharmaceutical Factory, established in 1973. The company spans an area of 80 acres, encompassing over 50,000 square meters, and employs 310 staff members.
As a rapidly growing pharmaceutical enterprise in China, Kaiwei Pharmaceutical has long been dedicated to the production and sales of small-volume injections. Since its inception, the company has been based in Zhangjiakou, committed to producing high-quality, competitively priced drugs, and focusing on the export and contract manufacturing of small-volume injections (intravenous injections). Its newly established high-level injection production line has obtained GMP certification from China's CFDA, Uganda's NDA, and other international regulatory organizations.
Kaiwei Hengcheng Pharmaceutical has earned widespread recognition from customers and the market for its stable performance in product quality, customer relations, and production costs. The company is not only a trusted partner for export processing commissioned by pharmaceutical enterprises such as Huayao International, Shiyao Ouyi, Shanghai Pharmaceuticals, and Lukang, but also an active participant in markets with high quality requirements, such as Russia and South America. Its products are sold to over 50 countries and regions worldwide, with the main markets concentrated in the Middle East, Southeast Asia, the CIS region of Russia, South America, and Africa.
Starting from a state-owned enterprise, Kaiwei Pharmaceutical has evolved into a private enterprise after over 40 years of development and restructuring. During the privatization process, the company has undergone numerous changes, including the construction of new production facilities in accordance with the new GMP standards of the country, the establishment of a high-end research and development as well as marketing platform covering developed countries in Europe and America, the improvement of production efficiency, the formation of a younger, more knowledgeable, and international management team and talent pool, and the ongoing construction of high-end generic drug projects targeting mainstream markets in Europe and America. These changes have significantly enhanced the company's sustainable profitability and growth potential, pushing Kaiwei Pharmaceutical to a new stage of development.
The pharmaceutical CMO industry is a field that receives strong support from the government. In recent years, the government has introduced a series of major policies to support industrial development, leading to a continuous growth in the national CMO market scale. In the summary of the number of entrustments received by CMO enterprises nationwide in 2022, our company ranked 12th.
The company's professional expertise is reflected in its distinctive hospital drugs and medical devices, with a long-term focus on sterile products. We pursue rapid response, aiming for first-to-market and first-generic products. Leveraging our proprietary platform and international registration advantages, we achieve the first-to-market launch of our products. We focus on key areas and utilize our combined strengths to delve deeply into specialized fields. The company's internationalization is reflected in its top-level design, product development, production quality management system, and marketing, which are aligned with international standards. Our advantageous products cover major pharmaceutical markets worldwide. Our R&D strategy can be summarized as "R&D in one location, application in three locations," while our channel strategy is "production in one factory, global sales.".
The company adheres to the corporate philosophy of "Virtue supports great undertakings, and self-cultivation fosters excellence", emphasizing product research and development, ensuring product quality from the source, and continuously striving to develop high-quality innovative and generic drugs globally. Through constantly embracing challenges and investing heavily in drug research and development, Hebei Kaiwei Hengcheng Pharmaceutical Co., Ltd. will gradually grow into a medium-sized innovative pharmaceutical and healthcare enterprise with a certain international reputation, showing utmost sincerity and care for every patient who uses Kaiwei's drugs worldwide.
Corporate purpose: Virtue supports great undertakings, and self-cultivation fosters excellence. Corporate mission: Born from love, working for love. Corporate vision: To become a leading enterprise in the field of rare disease treatment.
